General
Preferred name
NITROXOLINE
Synonyms
5-Nitro-8-quinolinol ()
8-Hydroxy-5-nitroquinoline ()
5-Nitro-8-hydroxyquinoline ()
5-nitroquinolin-8-ol ()
8-Hydroxy-5-nitroquinoline, 5-nitroquinolin-8-ol, 5-Nitro-8-quinolinol|5-Nitro-8-hydroxyquinoline ()
PMID27998201-Compound-22 ()
Pharmaprojects No. 3064 ()
8-Hydroxy-5-nitroquinoline, 5-nitroquinolin-8-ol, 5-Nitro-8-quinolinol, 5-Nitro-8-hydroxyquinoline ()
NSC-74947 ()
A-82 ()
Nitroxolina ()
P&D ID
PD000164
CAS
4008-48-4
Tags
available
drug
Drug indication
bacterial disease
Pancreatitis
Osteoarthritis
Alzheimer disease
Neurodegenerative disorder
Drug Status
experimental
approved
withdrawn
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Nitroxoline is an antimicrobial used to treat urinary tract infections . Repurposing of nitroxoline for infectious diseases and oncological indications has been proposed, although pharmacokinetic challenges are likely to hamper clinical translation.
From a patent it would appear that Healx Ltd. are interested in pursuing nitroxoline for the treatment of plexiform neurofibroma/neurofibromatosis type 1 (NF1) . Review of Healx's active pipeline (January 2026) reveals two candidates with codes HLX-1502 and HLX-0213 in development for NF1 . HLX-1502 has reached phase 2 whereas HLX-0213 is in the discovery phase (at time of writing), so it is plausible that HLX-1502 is nitroxoline. We await formal disclosure of this potential association. (GtoPdb)
From a patent it would appear that Healx Ltd. are interested in pursuing nitroxoline for the treatment of plexiform neurofibroma/neurofibromatosis type 1 (NF1) . Review of Healx's active pipeline (January 2026) reveals two candidates with codes HLX-1502 and HLX-0213 in development for NF1 . HLX-1502 has reached phase 2 whereas HLX-0213 is in the discovery phase (at time of writing), so it is plausible that HLX-1502 is nitroxoline. We await formal disclosure of this potential association. (GtoPdb)
DESCRIPTION
Nitroxoline (8-Hydroxy-5-nitroquinoline), an antibiotic, is an orally active antibiofilm agent. Nitroxoline reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc. Nitroxoline can be used for the urinary tract infections and cancer research[1][2][3].
PRICE
29
DESCRIPTION
Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections.
(Enamine Bioactive Compounds)
DESCRIPTION
Nitroxoline is a urinary antibacterial agent had proven to be very effective at combating biofilm infections.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Nitroxoline (5-nitroquinolin-8-ol) is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
3
Organisms
9
Compound Sets
23
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
59
Molecular Weight
190.04
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
2
Aromatic Ring Count
2
cLogP
1.85
TPSA
76.26
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
1
Redox
Redox cycling
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Pathway
Autophagy
Microbiology/virology
Anti-infection
Apoptosis
Member status
virtual
MOA
Antibiotic
Chelator
Methionine Aminopeptidase-2 (MetAP2) Inhibitors
Angiogenesis Inhibitors
Cathepsin inhibitor
Indication
urinary tract infections
Target
METAP2
Cathepsin B,Cysteine Protease
antibiotic
Bacterial
Antibacterial
Solubility
Soluble in DMSO
Source data
